

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A composition suitable for administration to a subject, said composition comprising a virus or a cell and a fusion polypeptide, said fusion polypeptide comprising

a first amino acid sequence which comprises a cell—surface binding moiety

and

a second amino acid sequence comprising a ligand for a cell surface polypeptide of a leukocyte,

wherein said ~~vaccine~~-composition includes said fusion polypeptide bound to said virus or said cell and includes said fusion polypeptide which is not bound to said virus or said cell, and wherein said fusion polypeptide is bound to a lipid on said virus or said cell by said cell—surface binding moiety.

2. (Previously presented) The composition of claim 1, wherein said ligand of said second amino acid sequence is chosen from the group consisting of: a ligand for a cytokine receptor, a ligand for CD40, a ligand for an adhesion molecule, a ligand for a defensin receptor, a ligand for a heat shock protein receptor, a ligand for a T cell costimulatory molecule, a ligand for a counterreceptor for a T cell costimulatory molecule, a ligand for an opsonin receptor.

3. (Currently amended) The ~~vaccine~~-composition of claim 2 wherein said ligand comprises at least five contiguous amino acids of a naturally occurring cytokine, said cytokine being chosen from the group: GM-CSF, an interleukin, a chemokine, an interferon, a TNF-alpha, a flt-3 ligand.

4. (Withdrawn – currently amended) The ~~vaccine~~-composition of claim 2 wherein said ligand comprises at least about five contiguous amino acids of a naturally occurring CD154 molecule.

5. (Previously Presented) The composition of claim 1, wherein said cell is chosen from the group consisting of: a tumor cell, a bacterial cell, a fungal cell, a cell of a parasite, a mammalian cell, an insect cell.
6. (Previously Presented) The composition of claim 5, wherein said cell is pathogenic.
7. (Previously Presented) The composition of claim 5, wherein said cell is attenuated.
8. (Previously Presented) The composition of claim 1, wherein said cell is substantially unable to divide.
9. (Previously Presented) The composition of claim 1, wherein said leukocyte is an antigen presenting cell.
10. (Previously Presented) The composition of claim 9, wherein said leukocyte is a professional antigen presenting cell.
11. (Previously Presented) The composition of claim 9, wherein said leukocyte is a dendritic cell.